U.S. stock futures rose, indicating the Standard & Poor�� 500 Index will gain for a second day, as investors awaited data that may show housing starts climbed and the start of a Federal Reserve policy meeting.
Walter Energy Corp. advanced 4.3 percent in New York pre-market trading York as Morgan Stanley said the coal miner�� shares may triple.
Futures on the S&P 500 (SPX) expiring in September increased 0.2 percent to 1,637.5 at 6:30 a.m. in New York. The index climbed 0.8 percent yesterday as data showed manufacturers in the New York area felt more optimistic in June and as confidence among U.S. homebuilders rose. Contracts on the Dow Jones Industrial Average gained 32 points, or 0.2 percent, to 15,153 today.
��.S. companies are doing really quite well,��James McCaughan, chief executive officer of Principal Global Investors LLC, told Mark Barton on Bloomberg Television. ��here�� low energy costs, high productivity, an improving housing market. All that means that U.S. companies, particularly domestics, are doing pretty well. It�� easy to see a situation for the rest of the year where U.S. equities continue to rise.��
Top 5 Consumer Service Companies To Buy For 2016: Iliad SA (ILD)
Iliad SA is a France-based holding company active in the integrated telecommunications sector. The Company provides Internet access services, hosting services and others. Iliad SA is also focused on fixed-line telephony services and the provision of wireless fidelity (WiFi) cards, among several others. In addition, Iliad SA sells via Internet a range of insurance policies. As of December 31, 2012, the Company had a number of subsidiaries, which include Free SAS, Centrapel SAS, Freebox SAS, Telecom Academy SARL, Free Frequences SAS, Iliad 1 SAS, Iliad 2 SAS, Protelco SAS, IFW SAS, IRE SAS, Management Centre De Relation Abonne (MCRA), F Distribution SAS, and Centrapel SAS, among others. Its Fixe subsidiary is a landline business-provider of broadband Internet services. As of year-end 2012, the Company was active as a operator in more than 35 countries. Advisors' Opinion:- [By Marie Mawad]
Sales and earnings at Orange are falling as domestic competition with rivals including discounter Iliad SA (ILD) weighs on prices. The carrier, which has diversified into countries from Poland to Egypt, is also trying to keep a lid on debt.
- [By Patricio Kehoe]
In order to counter the aggressive pricing strategy from wireless new entrant Iliad SA (ILD) in France, Orange was forced to reduce prices. Thus, the firm has continued to add wireless subscribers but at a lower average revenue per user, mainly through its low-end Sosh brand.
10 Best Sliver Stocks To Invest In Right Now: Mining Minerals of Mexico Corp (WIIM)
Mining Minerals of Mexico, Corp., formerly Cal Alta Auto Glass, Inc., incorporated on October 14, 1999, specializes in the repair and replacement of damaged glass windows on automobiles, including recreational vehicles (RVs) and Motorhomes. The Company uses only factory-authorized glass. It specializes in all foreign and domestic makes and models.
The Company uses other equipment manufacturer (O.E.M.)-rated adhesives and rust inhibiting primer's (manufactured by Dow Automotive). Based in Canada, it has two Auto Glass facilities servicing its customers. The Company stocks its own windshields at each of its locations throughout Calgary.
Advisors' Opinion:- [By Peter Graham]
Small cap mining stocks International Star Inc (OTCMKTS: ILST) and Mining Minerals of Mexico Corp (OTCMKTS: WIIM) sank 13.33% and 24.9%, respectively, today, with at least one of these small cap stocks being the subject of paid promotions or investor relations type of activities while the other has had no news since last summer. So should you dig into these small cap mining stocks which just dug a hole for investors and traders alike? Here is a closer look to help you decide:
10 Best Sliver Stocks To Invest In Right Now: YPF Sociedad Anonima(YPF)
YPF SOCIEDAD ANONIMA, an energy company, engages in the exploration, development, and production of crude oil, natural gas, and liquefied petroleum gas (LPG) in Argentina. The company also involves in refining, marketing, transportation, and distribution of oil and a range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels; and gas separation and natural gas distribution operations. As of December 31, 2010, it had proved reserves of approximately 531 million barrels of oil and 2,533 billion cubic feet of gas; and retail distribution network of 1,622 YPF-branded service stations for automotive petroleum products. The company?s crude oil transportation network includes approximately 2,700 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; crude oil tankage of approximately 7 million barrels; and terminal facilities at 5 Argentine ports. In addition, it participates in 3 power stations with an aggregate installed capacity of 1,622 megawatts. The company was founded in 1977 and is based in Buenos Aires, Argentina. YPF SOCIEDAD ANONIMA is a subsidiary of Repsol YPF, S.A.
Advisors' Opinion:- [By Garrett Cook]
Energy shares dropped around 0.22 percent in today’s trading. Top decliners in the sector included Daqo New Energy (NYSE: DQ), PDC Energy (NASDAQ: PDCE), and YPF SA (NYSE: YPF).
10 Best Sliver Stocks To Invest In Right Now: Theravance Inc.(THRX)
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The company?s key development programs with GlaxoSmithKline (GSK) include the RELOVAIR, a Phase 3 clinical trial program for the treatment of patients with chronic obstructive pulmonary disease (COPD) and/or asthma; the LAMA/LABA program, a Phase 3 COPD program; and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program, a Phase 2b program for the treatment of COPD, as well as Peripherally Selective Mu-Opioid Receptor Antagonist (P Advisors' Opinion:
- [By Sean Williams]
What: Shares of Theravance (NASDAQ: THRX ) , a biopharmaceutical company that focuses on central nervous system and respiratory disorders, leapt as much as 19% -- its second double-digit jump this week -- following a positive recommendation from the Food and Drug Administration's panel regarding COPD drug Breo Ellipta.
- [By Roberto Pedone]
Another biotechnology player that insiders are snapping up a large amount of stock in here is Theravance (THRX), which is a royalty management company, that is focused on developing respiratory products. Insiders are buying this stock into major weakness, since shares have collapsed badly so far in 2014 by 59%.
Theravance has a market cap of $1.6 billion and an enterprise value of $2 billion. This stock trades at a premium valuation, with a price-to-sales of 578.58. Its estimated growth rate for this year is 17.4%, and for next year it's pegged at 92%. This is not a cash-rich company, since the total cash position on its balance sheet is $310.86 million and its total debt is $705.11 million. This stock currently sports a dividend yield of 3.3%.
A beneficial owner just bought 832,456 shares, or around $12.78 million worth of stock, at $15.36 per share.
From a technical perspective, THRX is currently trending well below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last four months, with shares dropping from its high of $31.45 to its new 52-week low of $14.50 a share. During that downtrend, shares of THRX have been making mostly lower highs and lower lows, which is bearish technical price action.
If you're in the bull camp on THRX, then I would look for long-biased trades as long as this stock is trending above its new 52-week low of $14.50 a share and then once it breaks out above some key near-term overhead resistance levels at $16.61 to its 50-day moving average of $17.94 a share and then above more resistance at $18.68 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 824,188 shares. If that breakout triggers soon, then THRX will set up to re-test or possibly take out its next major overhead resistance levels at $21 to $22, or even its 200-day moving average of $23.58 a sh
10 Best Sliver Stocks To Invest In Right Now: Fusion-io Inc (FIO)
Fusion-io Inc (Fusion) is a provider of datacenter solutions that accelerate databases, virtualization, cloud computing, big data, and the applications that help drive business from the smallest e-tailers to some of the largest data centers, social media leaders, and Fortune Global 500 businesses. The Company's integrated hardware and software platform enables the decentralization of data from legacy architectures and specialized hardware. The Company sells its solutions through a global direct sales force, original equipment manufacturers, or OEMs, including Cisco, Dell, HP, and IBM, and other channel partners. In August 2011, the Company acquired IO Turbine, Inc.,. Effective March 18, 2013, the Company acquired ID7.
Fusion-io's ioMemory hardware is a sub-system connecting a large array of industry-standard NAND Flash memory through the Company's data-path controller and its virtual storage layer, or VSL, software to create a high capacity memory tier that natively attaches to a server's PCI-Express peripheral bus (PCIe).
The Company's portfolio of storage memory products incorporates the Company's ioMemory hardware combined with its virtual storage layer (VSL) and caching software into its family of ioDrive, ioFX, and ioCache enterprise grade products. The Company's ioDrive products work in conjunction with the Company's directCache data-tiering software, ioTurbine virtualization software, ioSphere management system, and ION Data Accelerator software. The Company's latest ioDrive, ioFX, and ioCache product families are a line of PCIe standard form-factor storage memory platforms that combine one or more ioMemory sub-systems with the Company's VSL software.
The Company's directCache software extends the Company's ioMemory based platforms and permits interoperability with traditional direct-attached, network-attached, storage area network attached, and appliance attached backend storage systems. The Company's ioTurbine virtualization software extends the Company! 's ioMemory platform and permits host-based data acceleration to specifically address the demand for high-density, high-performance server, and desktop virtualization.
ioSphere is a suite of management software purpose-built for the Company's storage memory infrastructure and designed around its application acceleration platform. ioSphere software is accessible through a graphical user interface that enables datacenter administrators to centrally configure, monitor, manage, and tune all distributed ioMemory devices throughout the datacenter. In addition, this software offers real-time, predictive, and historical reporting of ioMemory's performance and wear.
The Company's ION Data Accelerator software transforms server platforms into application acceleration appliances that share Fusion ioMemory across applications. ION Data Accelerator delivers Fusion-io performance on open server platforms with software-defined storage, or SDS, for applications such as Oracle RAC, Microsoft SQL Server, MySQL, and SAP HANA, along with other applications where shared storage aids deployment. The Company's original equipment manufacturer�� (OEMs), including Cisco, Dell, HP, and IBM, sell branded storage memory solutions based on the Company's standard products as well as custom form-factor versions to fit specific applications.
The Company competes with EMC Corporation, Hewlett-Packard Development Company, L.P, Texas Memory Systems, Oracle, Adaptec, Inc., LSI Corporation, Sandisk, Corp, IBM, CA, Inc, Nagios Enterprises, LLC., Hitachi Data, Huawei Technologies, Co., Intel Corp., LSI Corporation, Marvell Semiconductor, Inc., Micron Technology, Inc., OCZ Technology Group, Inc., Samsung Electronics, Inc., SanDisk, Corp., Seagate Technology, STEC, Inc., Toshiba Corp., and Western Digital Corp.
Advisors' Opinion:- [By Jesse Solomon]
The latest deals include medical device maker Medtronic's (MDT) $42.9 billion acquisition of rival Coviden (COV), telecom giant Level 3 Communications' (LVLT) $5.7 billion purchase of tw telecom (TWTC), Williams Companies (WMB)' $6 billion controlling stake in natural gas driller Access Midstream Partners (ACMP), and SanDisk's (SNDK) $1.1 billion takeover of flash technology company Fusion-io (FIO).
- [By Evan Niu, CFA]
What: Shares of Fusion-io (NYSE: FIO ) soared by as much as 21% today after the company posted strong earnings with an encouraging outlook.
10 Best Sliver Stocks To Invest In Right Now: NPS Pharmaceuticals Inc.(NPSP)
NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company?s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.
Advisors' Opinion:- [By Jake L'Ecuyer]
NPS Pharmaceuticals (NASDAQ: NPSP) was down, falling 10.78 percent to $29.58 after the company following a negative mention on Mad Money Thursday evening.�
- [By Keith Speights]
Although there is no cure for SBS, three drugs have been approved in the U.S. for treating the disease. The most recently approved treatment is Gattex. NPS Pharmaceuticals (NASDAQ: NPSP ) received Food and Drug Administration approval for the drug in late 2012. Gattex works by spurring growth in mucous membranes involved in absorption and secretion.
10 Best Sliver Stocks To Invest In Right Now: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Sean Williams]
Very few breakthrough therapies have been approved up to this point -- then again, we're only working with about 100 days for the Food and Drug Administration to have assigned such a designation. Vertex Pharmaceuticals'�received the first two "breakthrough therapy" designations from the FDA for two cystic fibrosis treatments, of which both involve the use of the already FDA-approved Kalydeco. The more intriguing "breakthrough therapy" designation is Pharmacyclics' (NASDAQ: PCYC ) Ibrutinib for the treatment of two rare blood cancers, which analysts feel could have a peak sales value of $5 billion if approved.
- [By Keith Speights]
Last year, Pharmacyclics (NASDAQ: PCYC ) shares gained a whopping 280%. That was enough to land the biotech a spot on The Motley Fool's list of top health-care stocks in 2012. How is 2013 looking so far? Shares have gained more than 30% year to date but have been anemic since early March.
No comments:
Post a Comment